Press release
POSITIVE PRE-IND MEETING WITH US FDA FOR NEW OVARIAN CANCER CELL THERAPY
Melbourne, Australia, 1 February 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its lead "off-the-shelf" natural killer (NK) cell therapy product, CTH-401 for the treatment of ovarian cancer.This is a significant milestone towards the filing of an Investigational New Drug (IND) application for CTH-401. The purpose of the meeting was to gain valuable guidance from the FDA on activities that need to be completed prior to submitting an IND application, particularly supporting non-clinical studies.
Cartherics received positive feedback on its development plan for CTH-401 that provides a clear path towards filing an IND and validates the Company's approach to the creation and development of CTH-401.
Cartherics CEO, Prof Alan Trounson AO, commented: "The pre-IND meeting for CTH-401 was a significant milestone for Cartherics and, based on the FDA's guidance, we are confident that we're on the path to a successful IND submission in early 2025."
CTH-401 is the only NK cell product currently under development that incorporates a chimeric antigen receptor (CAR) that targets the adenocarcinoma specific antigen,TAG-72. TAG-72 is a well-validated tumour marker that is widely expressed in a range of solid tumours, including ovarian, gastric, colorectal, prostate and pancreatic cancers. Cartherics has demonstrated that CTH-401 is very effective in killing ovarian cancer cells in both tissue culture and animal models, with initiation of the first clinical trial planned for early 2025.
Cartherics Pty Ltd
12 Ferntree Place
Notting Hill
Victoria, 3168
Australia
Cartherics media contact
Christine Filippis
Teraze Communications
Phone: +61 419 119 866
Email: christine@teraze.com.au
About Cartherics
Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body's immune system to fight cancer. It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products. The Company's allogeneic ("off-the-shelf") cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered at specific "safe harbour" genomic sites to provide enhanced function for the derived NK and other immune cells.
The Company is also developing autologous CAR-T cell therapies. These use the patient's own immune system T cells, which are modified to be effective against the patient's cancer cells. CTH-004 is created by genetically modifying patient T cells to insert a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes that are involved in suppression of T cell function. https://cartherics.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release POSITIVE PRE-IND MEETING WITH US FDA FOR NEW OVARIAN CANCER CELL THERAPY here
News-ID: 3369985 • Views: …
More Releases from Cartherics

CARTHERICS TO PRESENT AT THE 2025 BIO INTERNATIONAL CONVENTION
• Cartherics' Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US EDT).
Melbourne, Australia, 28 May 2025 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, COO, will present at the upcoming 2025 BIO International Convention June 16-19 2025, in Boston Massachusetts.…

CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO …
• Financing round was significantly oversubscribed by existing investors and new private investors.
• Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.
Melbourne, Australia, 1 October 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce…

CARTHERICS ENTERS AGREEMENTS WITH UNIQUEST, THE UNIVERSITY OF QUEENSLAND AND THE …
• Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics' iPSC cell line.
• Cartherics, The University of Queensland and The University of Sydney enter Material Transfer Agreement to support development of iPSC-derived cardiomyocytes for the treatment of cardiovascular disease.
Melbourne, Australia, 25 July 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that…

CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Melbourne, Australia, 23 May 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.
The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in…
More Releases for IND
Titanium Sponge Market: Complete Guide to Understanding Forecast (2023-2030): Ta …
The Titanium Sponge market report presents the global Titanium Sponge sales and revenue by companies, regions, types, and applications and forecast for 2028. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porter's Five Forces Analysis.
Titanium Sponge Market competition landscape by sales volume, Price (USD/Unit), revenue (Million USD), cost-profit analysis, and market share of…
3rd T20I 2021, SL vs IND Today Match Prediction 29th July
The third T20I of the 2021 Tour of Sri Lanka 2021 will see Sri Lanka and India clash at the R.Premadasa Stadium in Colombo on Thursday 29 July 2021. Read on to find out who the winner of today's 3rd T20I is. Travel to India, Sri Lanka on July 29, 2021.
India's travel to Sri Lanka has been fraught with ups and downs. First, a confirmed case of Corona 19 at…
Global Curcumin Market 2019 - Synthite Ind, Sabinsa, Indena, Biomax
This new report by Eon Market Research, titled “Global Curcumin Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Curcumin industry at a global as well as regional and country level. Key facts analyzed in this report include the Curcumin market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive…
Global Curcumin Market: Tairui Biotech, Synthite Ind,Zhongda Bio, Tianxu Biotech
Global Market Study Evaluate on Curcumin Industry by Type, Manufacturers, Application, Type, and Regions, Forecast up to 2022.The scope of the global Curcumin market report is:
This report offers a comprehensive evaluation of the Curcumin market. It does so by in-depth qualitative insights, historical Curcumin market data, and verifiable projections about global Curcumin market size. The projections featured in the Curcumin market report have been derived using proven research assumptions and…
Curcumin Market 2016 - Synthite Ind, Sabinsa, Indena, Biomax, K.Patel Phyto,
The Global Curcumin Market 2016 Industry Research Report focused on major manufacturers, regions, type as well as application of the Curcumin industry.
Curcumin is an ingredient of turmeric which is found in limited amounts in ginger. It is not water-soluble, but it is soluble in ethanol. It has excellent properties such as anti-inflammatory and anti-oxidation. It is extracted from turmeric and is widely used in pharmaceuticals, food and cosmetics industry…
Technology Innovation Award for IND iMobile Banking
1st April 2009- BUDAPEST, Hungary – The prestigious award, Innovation Grand Prize recognized by The Hungarian Association for Innovation was presented by The President of the Republic of Hungary Mr. László Sólyom at the dignified ceremony held in Hungarian Parliament’s Upper House Hall on last Friday.
IND Group’s software product, IND iMobile Banking presented at last year’s CEBIT with a great success, received the glittering Technology Innovation Award at 17th…